Novo Nordisk Exits Inflammation R&D To Focus More On Diabetes, Obesity
This article was originally published in The Pink Sheet Daily
Danish insulin maker’s decision triggered by failure of its most advanced compound, anti-IL-20, for the treatment of rheumatoid arthritis.
You may also be interested in...
J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.
Bristol-Myers Squibb launched its $885-million tender offer for Seattle biotech ZymoGenetics Sept. 10, with two major shareholders representing more than a third of the biotech's shares already on board. The acquisition would give Bristol full rights to a mid-stage interferon treatment for hepatitis C that it currently shares with ZymoGenetics.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.